{"id":51241,"date":"2022-11-25T12:02:04","date_gmt":"2022-11-25T11:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/"},"modified":"2022-11-25T12:02:04","modified_gmt":"2022-11-25T11:02:04","slug":"global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/","title":{"rendered":"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5240450\/chronic-hepatitis-delta-virus-hdv-infection?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=czxlvf&amp;utm_campaign=1780447+-+Global+Chronic+Hepatitis+Delta+Virus+(HDV)+Infection+Drug+Pipeline+Insight+Report+2022%3A+Comprehensive+Insights+About+10%2B+Companies+and+10%2B+Pipeline+Drugs&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Chronic Hepatitis Delta Virus (HDV) Infection &#8211; Pipeline Insight, 2022&#8221;<\/a> clinical trials has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221125005130\/en\/1647049\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221125005130\/en\/1647049\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape.\n<\/p>\n<p>\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n<p>\nThe assessment part of the report embraces, in depth Chronic Hepatitis Delta Virus (HDV) Infection commercial assessment and clinical assessment of the pipeline products under development.\n<\/p>\n<p>\nIn the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis Delta Virus (HDV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\n<\/p>\n<p>\n<strong>Report Highlights<\/strong>\n<\/p>\n<p>\nThe companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&amp;D. The therapies under development are focused on novel approaches to treat\/improve Chronic Hepatitis Delta Virus (HDV) Infection.\n<\/p>\n<p>\n<strong>Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Chapters<\/strong>\n<\/p>\n<p>\nThis segment of the Chronic Hepatitis Delta Virus (HDV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n<p>\n<strong>Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs<\/strong>\n<\/p>\n<p>\n<strong>Lonafarnib: Eiger Biopharmaceuticals<\/strong>\n<\/p>\n<p>\nEiger&#8217;s lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.\n<\/p>\n<p>\n<strong>JNJ-73763989: Janssen Pharmaceuticals<\/strong>\n<\/p>\n<p>\nJanssen &#8220;breakthrough&#8221; drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral class molecule designed to treat HVB and HVD infection via RNA interference mechanism. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.\n<\/p>\n<p>\n<strong>Chronic Hepatitis Delta Virus (HDV) Infection: Therapeutic Assessment<\/strong>\n<\/p>\n<p>\nThis segment of the report provides insights about the different Chronic Hepatitis Delta Virus (HDV) Infection drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n<p>\n<strong>Major Players in Chronic Hepatitis Delta Virus (HDV) Infection<\/strong>\n<\/p>\n<p>\nThere are approx. 10+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III include, Eiger Biopharmaceuticals.\n<\/p>\n<p>\n<strong>Phases<\/strong>\n<\/p>\n<p>\n<strong>This report covers around 10+ products under different phases of clinical development like<\/strong>\n<\/p>\n<ul>\n<li>\nLate-stage products (Phase III)\n<\/li>\n<li>\nMid-stage products (Phase II and Phase I\/II)\n<\/li>\n<li>\nEarly-stage products (Phase I\/II and Phase I) along with the details of\n<\/li>\n<li>\nPre-clinical and Discovery stage candidates\n<\/li>\n<li>\nDiscontinued &amp; Inactive candidates\n<\/li>\n<\/ul>\n<p>\n<strong>Route of Administration<\/strong>\n<\/p>\n<p>\nChronic Hepatitis Delta Virus (HDV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.\n<\/p>\n<p>\n<strong>Products have been categorized under various ROAs such as<\/strong>\n<\/p>\n<ul>\n<li>\nSubcutaneous\n<\/li>\n<li>\nIntravenous\n<\/li>\n<li>\nOral\n<\/li>\n<li>\nIntramuscular\n<\/li>\n<li>\nMolecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various Molecule types such as<\/strong>\n<\/p>\n<ul>\n<li>\nSmall molecules\n<\/li>\n<li>\nNatural metabolites\n<\/li>\n<li>\nMonoclonal antibodies\n<\/li>\n<li>\nProduct Type\n<\/li>\n<\/ul>\n<p>\nDrugs have been categorized under various product types like Mono, Combination and Mono\/Combination.\n<\/p>\n<p>\n<strong>Chronic Hepatitis Delta Virus (HDV) Infection: Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis Delta Virus (HDV) Infection therapeutic drugs key players involved in developing key drugs.\n<\/p>\n<p>\n<strong>Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis Delta Virus (HDV) Infection drugs.\n<\/p>\n<p>\n<strong>Chronic Hepatitis Delta Virus (HDV) Infection Report Insights<\/strong>\n<\/p>\n<ul>\n<li>\nChronic Hepatitis Delta Virus (HDV) Infection Pipeline Analysis\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<li>\nImpact of Drugs\n<\/li>\n<\/ul>\n<p>\n<strong>Chronic Hepatitis Delta Virus (HDV) Infection Report Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nPipeline Assessment\n<\/li>\n<li>\nInactive drugs assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Players<\/strong>\n<\/p>\n<ul>\n<li>\nJanssen Pharmaceuticals\n<\/li>\n<li>\nEiger Biopharmaceutical\n<\/li>\n<li>\nPharma Essentia\n<\/li>\n<li>\nVir Biotechnology, Inc.\n<\/li>\n<li>\nHuahui Health\n<\/li>\n<li>\nAntios Therapeutics\n<\/li>\n<\/ul>\n<p>\n<strong>Key Products<\/strong>\n<\/p>\n<ul>\n<li>\nJNJ-73763989\n<\/li>\n<li>\nLonafarinib\n<\/li>\n<li>\nP1101\n<\/li>\n<li>\nVIR 2218\n<\/li>\n<li>\nVIR 3434\n<\/li>\n<li>\nNivolumab\n<\/li>\n<li>\nHH 003\n<\/li>\n<li>\nATI 2173\n<\/li>\n<\/ul>\n<p>\nFor more information about this clinical trials report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5240450\/chronic-hepatitis-delta-virus-hdv-infection?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=czxlvf&amp;utm_campaign=1780447+-+Global+Chronic+Hepatitis+Delta+Virus+(HDV)+Infection+Drug+Pipeline+Insight+Report+2022%3A+Comprehensive+Insights+About+10%2B+Companies+and+10%2B+Pipeline+Drugs&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/wr0q5q<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;&#116;o&#x3a;&#x70;&#x72;&#101;&#115;s&#64;&#x72;&#x65;&#x73;&#101;&#97;r&#x63;&#x68;&#x61;&#110;&#100;&#109;a&#x72;&#x6b;&#x65;&#116;&#115;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;&#101;&#x73;&#115;&#x40;&#114;&#x65;s&#x65;a&#x72;c&#x68;a&#110;&#x64;&#109;&#x61;&#114;&#x6b;&#101;&#x74;&#115;&#x2e;c&#x6f;m<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Chronic Hepatitis Delta Virus (HDV) Infection &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51241","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Chronic Hepatitis Delta Virus (HDV) Infection &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-25T11:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221125005130\/en\/1647049\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-11-25T11:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/\"},\"wordCount\":835,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221125005130\\\/en\\\/1647049\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/\",\"name\":\"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221125005130\\\/en\\\/1647049\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-11-25T11:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221125005130\\\/en\\\/1647049\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221125005130\\\/en\\\/1647049\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Chronic Hepatitis Delta Virus (HDV) Infection &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-25T11:02:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221125005130\/en\/1647049\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs &#8211; ResearchAndMarkets.com","datePublished":"2022-11-25T11:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/"},"wordCount":835,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221125005130\/en\/1647049\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/","name":"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221125005130\/en\/1647049\/21\/logo.jpg","datePublished":"2022-11-25T11:02:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221125005130\/en\/1647049\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221125005130\/en\/1647049\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-chronic-hepatitis-delta-virus-hdv-infection-drug-pipeline-insight-report-2022-comprehensive-insights-about-10-companies-and-10-pipeline-drugs-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51241"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51241\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}